Sign in

    Greg Silvanouve

    Vice President and Equity Research Analyst at Mizuho

    Greg Silvanouve is a Vice President and Equity Research Analyst at Mizuho, specializing in U.S. software and cloud infrastructure companies. He provides research coverage on leading firms such as Salesforce, ServiceNow, Workday, Atlassian, and Twilio, with a proven track record of delivering actionable investment insights and achieving above-average performance on his stock recommendations. Silvanouve began his financial career in the early 2010s, with previous roles at J.P. Morgan and Jefferies before joining Mizuho in 2018 as part of their expanding technology research team. He holds FINRA Series 7, 63, and 86/87 licenses and has been recognized by institutional investors for the depth and accuracy of his industry analysis.

    Greg Silvanouve's questions to EyePoint Pharmaceuticals (EYPT) leadership

    Greg Silvanouve's questions to EyePoint Pharmaceuticals (EYPT) leadership • Q2 2025

    Question

    Sam on behalf of Greg Silvanouve at Mizuho asked about the physician feedback received at the recent ASRS meeting and what incremental data to expect from the full end-of-study VORONNA data presentation in September.

    Answer

    CEO Jay Duker described the feedback at ASRS as 'incredible' and 'positive,' with physicians excited about the new mechanism of action and the potential for a true six-month treatment extension. CMO Ramiro Ribeiro stated that the upcoming VORONNA presentation will build on previously shared data regarding BCVA, CST, and treatment burden, but did not disclose further specifics ahead of the meeting.

    Ask Fintool Equity Research AI